United States was Integrated Biopharma’s largest region in fiscal 2026, bringing in $33.75M of $42.39M (80%).
| Geography | FY 2012 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $40.23M | $40.62M | $40.96M | $33.75M | |||||||
| Us Customers | — | — | — | — | |||||||
| International Customers | — | — | — | — | |||||||
| Non-Us | $8.05M | $7.95M | $10.73M | $8.64M | |||||||
| Total | $48.28M | $48.57M | $51.68M | $42.39M |
Integrated Biopharma brought in $42.39M from its two regions in fiscal 2026, the year ended June 30, 2026. That was down 18.0% from $51.68M in fiscal 2025. United States was the largest at $33.75M (79.6%), ahead of Non-Us at $8.64M (20.4%).
Compared with fiscal 2025, United States fell 17.6% to $33.75M and Non-Us fell 19.4% to $8.64M. From fiscal 2023 to 2026, combined revenue from these regions fell from $48.28M to $42.39M, a compound annual decline of 4.2%. United States' share of the total fell from 83.3% to 79.6%.
Contract Manufacturing was Integrated Biopharma’s largest segment in fiscal 2026, bringing in $33.75M of $35.23M (96%).
| Statement Business Segments | FY 2012 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Contract Manufacturing | $40.23M | $40.62M | $40.96M | $33.75M | |||||||
| Branded Proprietary Products | — | — | — | — | |||||||
| Other Nutraceutical Business | $2.39M | $1.72M | $2.67M | $1.48M | |||||||
| Total | $42.62M | $42.34M | $43.63M | $35.23M |
Integrated Biopharma brought in $35.23M from its two segments in fiscal 2026, the year ended June 30, 2026. That is less than the $42.39M it reports by geography, so these segments do not cover all of its revenue. Contract Manufacturing was the largest at $33.75M (95.8%), ahead of Other Nutraceutical Business at $1.48M (4.2%).
Compared with fiscal 2025, Contract Manufacturing fell 17.6% to $33.75M and Other Nutraceutical Business fell 44.4% to $1.48M.
Integrated Biopharma (INBP) reports its revenue by geography and by statement business segments. In fiscal 2026, United States was its largest region, bringing in $33.75M (79.6% of the total), followed by Non-Us at $8.64M (20.4%).
United States was Integrated Biopharma's largest region in fiscal 2026, bringing in $33.75M, or 79.6% of the $42.39M total across its two regions.
Contract Manufacturing was Integrated Biopharma's largest segment in fiscal 2026, bringing in $33.75M, or 95.8% of the $35.23M total across its two segments.
Every figure comes from Integrated Biopharma's annual financial filings, as reported. Each line keeps the name Integrated Biopharma gives it, and years follow its fiscal calendar.
Integrated Biopharma's revenue by geography goes back to fiscal 2012, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.